Abstract Number: 0276 • ACR Convergence 2020
Type 2 SLE Symptoms Persist Despite Type 2 Medication Polypharmacy
Background/Purpose: Management of Type 2 SLE (widespread pain, fatigue, depression, sleep distrubance, and cognitive dysfunction) is challenging and often requires multiple medications to ameliorate symptoms.…Abstract Number: 0294 • ACR Convergence 2020
Tired T-Cells and Monocytes with Malaise: Investigating the Links Between Cellular Iron Deficiency and Mitochondrial Dysfunction in Systemic Lupus Erythematosus
Background/Purpose: Iron is vital for many physiological processes and is found within respiratory complexes of the mitochondrial electron transport chain, the key site of oxidative phosphorylation…Abstract Number: 0439 • ACR Convergence 2020
Hurried Communication and Low Patient Self-Efficacy Are Associated with Persistent Non-Adherence to SLE Medications
Background/Purpose: Medication non-adherence is common among SLE patients and contributes to poor outcomes. Underrepresented racial minorities have disproportionately lower rates of medication adherence and often…Abstract Number: 0577 • ACR Convergence 2020
Qualitative Review of Unsuccessful Pilot Study of Super-Utilizer Systemic Lupus Erythematosus (SLE) Patients Enrollment into Team Based Program to Improve Patient Outcomes
Background/Purpose: SLE is a chronic multi-system autoimmune disease, affecting mostly women of child-bearing age and more racial minorities, with a wide spectrum of outcomes: from…Abstract Number: 0842 • ACR Convergence 2020
mTOR Signaling Pathway Blockade and Rab4 Expression Affects Metabolism of Lupus T Cells
Background/Purpose: Pro-inflammatory T-cell development underlies the pathogenesis of systemic lupus erythematosus (SLE). Activation of the mechanistic target of rapamycin (mTOR) plays a central role in…Abstract Number: 0861 • ACR Convergence 2020
Hydroxychloroquine Use Is Associated with Diminished Type I Interferon-related Pathways in Systemic Lupus Erythematosus Patients
Background/Purpose: Hydroxychloroquine (HCQ) has been used for decades to treat systemic lupus erythematosus (SLE) and is associated with decreased lupus flares and damage. However, despite…Abstract Number: 0975 • ACR Convergence 2020
Gasdermin D Modulates Murine Lupus and Its Associated Organ Damage
Background/Purpose: Gasdermin D (GSDMD) is the key executioner of the inflammatory cell death mechanism pyroptosis. Recent reports have also implicated GSDMD in other mechanisms of…Abstract Number: 1021 • ACR Convergence 2020
Organ Damage in Systemic Lupus Erythematosus Is Attributable More to Comorbidity (Hypertension) and Less to Socioeconomic Status
Background/Purpose: Multiple variables are known to contribute to development of organ damage in SLE patients, including prednisone use and ethnicity. The aim of this study…Abstract Number: 1258 • ACR Convergence 2020
Trajectory of Damage Accrual in African-American vs. Caucasian Systemic Lupus Erythematosus
Background/Purpose: African-Americans have a higher incidence/prevalence of SLE, more lupus nephritis, higher rates of end stage renal disease and higher mortality than Caucasians. The aim…Abstract Number: 1275 • ACR Convergence 2020
Unexpected Changes in Physical and Psychological Measures Among Georgia Lupus Patients During the Early Weeks of the COVID-19 Pandemic in the United States, March 30–April 21, 2020
Background/Purpose: An infectious disease outbreak can lead to negative physical and psychological consequences in the general public, as shown by the early COVID-19 pandemic, through…Abstract Number: 1291 • ACR Convergence 2020
Depressed Symptomatology Persists over Time in the Majority of Systemic Lupus Erythematosus Patients and Is Independent of Disease Activity
Background/Purpose: Depression is a prevalent (24-30%) and significant comorbidity in patients with systemic lupus erythematosus (SLE) (1). As the American College of Rheumatology (ACR) classifies…Abstract Number: 1461 • ACR Convergence 2020
Implementation, Feasibility and Acceptability of Take Charge, an Email Series to Increase Knowledge of Lupus Self-Management Skills
Background/Purpose: The Lupus Foundation of America developed and launched an educational email series, Take Charge, to provide people with lupus educational information, tools and resources…Abstract Number: 1565 • ACR Convergence 2020
Joint Cartilage Damage Evaluated by Ultrasound in Patients with Systemic Lupus Erythematosus
Background/Purpose: Arthritis in systemic lupus erythematosus (SLE) is typically non-erosive, although some patients with SLE show erosive destruction or Jaccoud’s arthropathy. Previously we have confirmed…Abstract Number: 1676 • ACR Convergence 2020
Neuropsychiatric Involvement in Juvenile-onset Systemic Lupus Erythematosus (JSLE): Data from the UK JSLE Cohort Study
Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is a rare autoimmune/inflammatory disease, accounting for up to 20% of SLE cases. Though clinically similar to adult-onset disease,…Abstract Number: 1787 • ACR Convergence 2020
Differences in Chromatin Architecture Between Treatment Naïve Pediatric and Adult Lupus Patients
Background/Purpose: Systemic lupus erythematosus (SLE) is possibly triggered by gene-environment interactions. We showed most of the SLE haplotypes encompass genomic regions enriched for epigenetic marks…
- « Previous Page
- 1
- …
- 121
- 122
- 123
- 124
- 125
- …
- 150
- Next Page »